Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report-Reference-Cited by-同舟云学术

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

Published:2014-07-26 Issue:3 Volume:167 Page:394-401
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Goldman Stanton¹,Smith Lynette²,Galardy Paul³,Perkins Sherrie L.⁴,Frazer John Kimble⁵,Sanger Warren⁶,Anderson James R.²,Gross Thomas G.⁷,Weinstein Howard⁸,Harrison Lauren⁹,Shiramizu Bruce¹⁰,Barth Matthew¹¹,Cairo Mitchell S.⁹¹²¹³¹⁴¹⁵

Affiliation:

1. Division of Pediatric Hematology/Oncology; Medical City Children's Hospital; Dallas TX USA

2. Department of Biostatistics; College of Public Health; University of Nebraska; Omaha NE USA

3. Department Pediatric Hematology/Oncology; Mayo Clinic; Rochester MN USA

4. Department of Pathology; University of Utah; Salt Lake City UT USA

5. Section of Pediatric Hematology-Oncology; University of Oklahoma Health Sciences Center; Oklahoma City OK USA

6. Center for Human Genetics; University of Nebraska; Omaha NE USA

7. Center for Global Health; National Cancer Institute; National Institute of Health; Rockville MD USA

8. Division of Pediatric Hematology/Oncology; Massachusetts General Hospital; Harvard Medical School; Boston MA USA

9. Department of Pediatrics; New York Medical College; Valhalla NY USA

10. Division of Pediatric Hematology/Oncology; University of Hawaii; Honolulu HI USA

11. Department of Pediatrics; Roswell Park Cancer Institute; Buffalo NY USA

12. Department of Medicine; New York Medical College; Valhalla NY USA

13. Department of Pathology; New York Medical College; Valhalla NY USA

14. Department of Microbiology and Immunology; New York Medical College; Valhalla NY USA

15. Department of Cell Biology and Anatomy; New York Medical College; Valhalla NY USA

Funder

National Institutes of Health

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13040/fullpdf

Reference22 articles.

1. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis;Barnes;Annals of Oncology,2011

2. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report;Barth;British Journal of Haematology,2013

3. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents;Cairo;Blood,2007

4. Advanced stage, elevated LDH and primary site, but not adolescent age (≥15 years), are associated with an increased risk of failure in children and adolescents with mature B-NHL: results of the FAB/LMB 96 study;Cairo;Journal of Clinical Oncology,2012

5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;New England Journal of Medicine,2002

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults;Journal of the National Comprehensive Cancer Network;2024-07

2. Mature B‐cell lymphomas in adolescents and young adults;eJHaem;2023-09-08

3. Translocation Tales: Unraveling the MYC Deregulation in Burkitt Lymphoma for Innovative Therapeutic Strategies;Lymphatics;2023-07-11

4. Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults;Best Practice & Research Clinical Haematology;2023-06

5. Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review;Pediatric Health, Medicine and Therapeutics;2023-05